Amgen: Purpura, Thrombocytopenic, Idiopathic trials

The registry lists 18 Purpura, Thrombocytopenic, Idiopathic studies with Amgen as lead sponsor. 1 are open to participants now and 13 have results posted.

Phase 1 2Phase 2 4Phase 3 10Phase 4 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)RecruitingNCT07700238Phase 3
• Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)CompletedNCT02279173Phase 3Results posted
• Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric PatientsCompletedNCT01444417Phase 3Results posted
• Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving RomiplostimCompletedNCT01143038Phase 2Results posted
• A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia PurpuraCompletedNCT01071954Phase 3Results posted
• Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)CompletedNCT00907478Phase 4Results posted
• P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic PurpuraCompletedNCT00603642Phase 3Results posted
• Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric SubjectsCompletedNCT00515203Phase 1/2Results posted
• An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITPCompletedNCT00508820Phase 3Results posted
• Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)CompletedNCT00454857Results posted
• Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic PurpuraCompletedNCT00415532Phase 3Results posted
• Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)CompletedNCT00117143Phase 1/2Results posted
• Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)CompletedNCT00116688Phase 3Results posted
• Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)CompletedNCT00111475Phase 2Results posted
• Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration TrainingCompletedNCT02085993
• Effects of Long-term Dosing of AMG 531 on Bone Marrow MorphologyCompletedNCT00861224
• AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to SplenectomyCompletedNCT00102336Phase 3
• AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to SplenectomyCompletedNCT00102323Phase 3